Edwin A Usmanij

Learn More
UNLABELLED The potential of (18)F-FDG PET changes was evaluated for prediction of response to concomitant chemoradiotherapy in patients with locally advanced non-small cell lung cancer (NSCLC). METHODS For 28 patients, (18)F-FDG PET was performed before treatment, at the end of the second week of treatment, and at 2 wk and 3 mo after the completion of(More)
BACKGROUND AND PURPOSE This study evaluated the use of total lesion glycolysis (TLG) determined by different automatic segmentation algorithms, for early response monitoring in non-small cell lung cancer (NSCLC) patients during concomitant chemoradiotherapy. MATERIALS AND METHODS Twenty-seven patients with locally advanced NSCLC treated with concomitant(More)
PURPOSE OF REVIEW The aim of this review is to provide an outline of current evidence for the use of F-18-fluoro-deoxy-glucose PET computed tomography (FDG-PET/CT) in nonsmall cell lung cancer (NSCLC) for diagnosis, staging, radiotherapy planning, response assessment and response monitoring. RECENT FINDINGS Management of patients with NSCLC requires a(More)
18F-FDG PET/CT is potentially applicable to predict response to chemotherapy in combination with bevacizumab in patients with advanced non-small cell lung cancer (NSCLC). Methods: In 25 patients with advanced nonsquamous NSCLC, 18F-FDG PET/CT was performed before treatment and after 2 wk, at the end of the second week of first cycle carboplatin-paclitaxel(More)
We commended Bahce et al. for their excellent paper entitled Metabolic activity measured by FDG PET predicts pathological esponse in locally advanced superior sulcus NSCLC” [1]. This tudy shows the prognostic and predictive performance of FDG ET in non-small cell lung cancer (NSCLC) in correlation with he post-induction pathological response. Metabolic(More)
  • 1